Skip to main content

Sorrento Therapeutics, Inc.

SRNEDelisted Apr 12, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000850261

Sorrento Therapeutics, Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Mar 20, 2023; 224 institutions reported holding it in 13F filings for Q4 2022, worth $180.7M in total; Oaktree Capital was the only superinvestor holding it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
224
Q4 2022, −6 vs. previous quarter
13F value
$180.7M
Reported value at the end of Q4 2022
Superinvestors holding
1
At the end of Q4 2022

Superinvestors holding SRNE, Q4 2022

1 superinvestor reports holding Sorrento Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

Oaktree Capital

Howard Marks

<0.1%

Sorrento Therapeutics, Inc.'s share of the portfolio

Shares
134,000
Value
$118.7K

Latest insider trades

Open-market purchases and sales by Sorrento Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 7, 2022 (view filing)Sep 7Same dayJi HenrySee RemarksPPurchase+88.9K$2.02+$179.6K+1.9%4.77M after
Sep 7, 2022 (view filing)Sep 7Same dayJi HenrySee RemarksPPurchase+88.8K$0.4081+$36.2K–129 afterDerivative2 lots
Sep 6, 2022 (view filing)Sep 6Same dayJi HenrySee RemarksPPurchase+55.6K$1.96+$108.9K+1.2%4.68M after
Aug 26, 2022 (view filing)Aug 26Same dayJi HenrySee RemarksPPurchase+33.3K$2.11+$70.3K+1.6%2.12M after
Aug 26, 2022 (view filing)Aug 26Same dayJi HenrySee RemarksSSale−20.0K$3.49−$69.9K–200 afterDerivative
Aug 25, 2022 (view filing)Aug 25Same dayJi HenrySee RemarksPPurchase+22.2K$2.06+$45.8K+1.1%2.09M after
Aug 25, 2022 (view filing)Aug 25Same dayJi HenrySee RemarksPPurchase+100.0K$0.3066+$30.7K–1.00K afterDerivative
Jun 14, 2022 (view filing)Jun 14Same dayJi HenrySee RemarksPPurchase+10.0K$1.40+$14.0K+0.5%2.07M after
Dec 27, 2021 (view filing)Dec 27Same dayJanda KimDirectorSSale−3.00K$5.88−$17.6K−50.0%3.00K after
Sep 28, 2021 (view filing)Sep 271 dayJanda KimDirectorSSale−42.4K$8.02−$339.7K−93.4%3.00K after

Top 10 13F holders, Q4 2022

The largest institutional positions in Sorrento Therapeutics, Inc. at the end of Q4 2022; share changes are against Q3 2022.

See all 224 holders
Institutions holding SRNE in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
State Street Corp50,637,571$44.9M0.00%+9,968,295+24.5%Added
BlackRock Inc.39,423,641$34.9M0.00%+5,244,074+15.3%Added
Vanguard Group Inc29,535,954$26.2M0.00%+7,019,380+31.2%Added
Geode Capital Management, LLC8,905,936$7.89M0.00%+1,797,652+25.3%Added
B. Riley Financial, Inc.5,216,250$4.62M1.04%+5,216,250New
B. Riley Securities, Inc.5,216,250$4.62M1.01%+5,216,250New
D. E. Shaw & Co., Inc.5,106,072$4.52M0.01%+49,109+1.0%Added
Rafferty Asset Management, LLC4,394,415$3.89M0.03%+1,399,741+46.7%Added
Northern Trust Corp4,180,871$3.70M0.00%+743,271+21.6%Added
Charles Schwab Investment Management Inc3,508,377$3.11M0.00%+674,716+23.8%Added